Prof. Jianyun Nie 聂建云
Chief Physician, Professor
Department of Breast Surgery, Yunnan Cancer Hospital, Kunming
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Breast cancer risk assessment, early diagnosis, minimally invasive radical surgery, and standardized comprehensive treatment. Also treats benign breast tumors and mammary hyperplasia.
Dr. Nie is Deputy Director of Yunnan Cancer Hospital and a Professor. Dr. Nie holds an MD and completed postdoctoral research at McGill University. With 25 years of clinical experience, Dr. Nie has performed over 5,000 breast cancer surgeries. Dr. Nie participated in drafting the Chinese Breast Cancer Diagnosis and Treatment Guidelines and serves as a doctoral supervisor.
Professional roles
- Standing Committee Member, Breast Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Standing Committee Member, Patient Education Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Breast Cancer Committee, China Anti-Cancer Association
- Chair, Breast Cancer Professional Committee, Yunnan Medical Doctor Association
Name order: in Chinese the family name comes first (Nie Jianyun). Papers usually list the name as Jianyun Nie or Nie J.
Selected publications
53 papers on PubMed matched by name and affiliation; 15 as first or senior author since 2016. Most recent first- or senior-author papers:
- Pathol Res Pract, 2026 (senior author): ACOD1 enhances the ferroptosis resistance of tumor-associated macrophages through the KEAP1/NRF2 axis and promotes triple-negative breast cancer progression. PubMed 42617477
- Front Oncol, 2026 (senior author): The multifaceted roles of mitochondria and their therapeutic transformation: a new perspective on triple-negative breast cancer treatment. PubMed 42394708
- Front Immunol, 2026 (senior author): Decoding the landscape of bispecific antibodies in breast cancer: insights from a comprehensive trial analysis. PubMed 42344894
- Front Oncol, 2026 (senior author): STAT3 inhibitor in oncology: a trial-based analysis of translational challenges and evolving therapeutic paradigms. PubMed 42180089
- Breast, 2026 (senior author): Focusing on toxicity management: Challenges and strategies for HER2-targeted antibody-drug conjugates in breast cancer. PubMed 41785741
- Breast Cancer (Dove Med Press), 2025 (senior author): LINC00917 Promotes Bone Metastasis of Breast Cancer by Targeting the miR-491-5p/FOXP4 Axis. PubMed 41133246
- Front Oncol, 2025 (senior author): Development and validation of nomograms for predicting grade ≥3 diarrhea and neutropenia after abemaciclib combined with endocrine therapy for breast cancer: a multicenter retrospective real-world study. PubMed 41122656
- Sci Rep, 2025 (senior author): Evaluation of self designed breast molds in enhancing doctor patient communication. PubMed 40461485
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion